Literature DB >> 8421063

Identification and characterization of a tumor cell receptor for CSVTCG, a thrombospondin adhesive domain.

G P Tuszynski1, V L Rothman, M Papale, B K Hamilton, J Eyal.   

Abstract

We have previously shown that peptides derived from the thrombospondin sequence, CSVTCG, promoted tumor cell adhesion. To further investigate this observation, the CSVTCG-tumor cell adhesion receptor from A549 human lung adenocarcinoma cells was isolated and characterized. A single protein peak was isolated by CSVTCG affinity chromatography which also analyzed as a single peak by anion exchange chromatography. The purified protein had a pI of 4.7 and analyzed on SDS-gels as a single band of M(r) = 50,000 under nonreducing conditions and as two protein bands of M(r) = 50,000, and 60,000 under reducing conditions. Purified CSVTCG binding protein (CBP) bound either CSVTCG- or TSP-Sepharose but showed little interaction with either VCTGSC- or BSA-Sepharose. CBP was cell surface exposed. CSVTCG derivatized with [125I] Bolton-Hunter reagent was taken up by cells in a dose-dependent manner and the cell association was inhibited with a monospecific polyclonal anti-CBP antibody. Examination of the cell proteins crosslinked to labeled CSVTCG by SDS-gel electrophoresis revealed one band that comigrated with purified CPB. Using an in vitro binding assay, purified CBP bound mannose, galactose, and glucosamine-specific lectins. CBP bound TSP saturably and reversibly. The binding was Ca+2/Mg+2 ion dependent and inhibited with fluid phase TSP and anti-CBP. Little or no binding was observed on BSA, fibronectin, GRGES, and GRGDS. Heparin, but not lactose, inhibited binding. Anti-CBP IgG and anti-CSVTCG peptide IgG inhibited A549 cell spreading and adhesion on TSP but not on fibronectin and laminin. These results indicate that CBP and the CSVTCG peptide domain of TSP can mediate TSP-promoted tumor cell adhesion.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8421063      PMCID: PMC2119506          DOI: 10.1083/jcb.120.2.513

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  36 in total

1.  Isolation and characterization of a high molecular weight glycoprotein from human blood platelets.

Authors:  J W Lawler; H S Slayter; J E Coligan
Journal:  J Biol Chem       Date:  1978-12-10       Impact factor: 5.157

2.  Thrombospondin binds normally to glycoprotein IIIb deficient platelets.

Authors:  B Kehrel; A Kronenberg; B Schwippert; D Niesing-Bresch; U Niehues; D Tschöpe; J van de Loo; K J Clemetson
Journal:  Biochem Biophys Res Commun       Date:  1991-09-16       Impact factor: 3.575

3.  A rapid method for removal of [125I]iodide following iodination of protein solutions.

Authors:  G P Tuszynski; L Knight; J R Piperno; P N Walsh
Journal:  Anal Biochem       Date:  1980-07-15       Impact factor: 3.365

4.  Monoclonal anti-human monocyte antibodies OKM1 and OKM5 possess distinctive tissue distributions including differential reactivity with vascular endothelium.

Authors:  D M Knowles; B Tolidjian; C Marboe; V D'Agati; M Grimes; L Chess
Journal:  J Immunol       Date:  1984-05       Impact factor: 5.422

5.  Thrombospondin-induced adhesion of human platelets.

Authors:  G P Tuszynski; M A Kowalska
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

6.  Antisense-mediated reduction in thrombospondin reverses the malignant phenotype of a human squamous carcinoma.

Authors:  V Castle; J Varani; S Fligiel; E V Prochownik; V Dixit
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

7.  Thrombospondin sequence motif (CSVTCG) is responsible for CD36 binding.

Authors:  A S Asch; S Silbiger; E Heimer; R L Nachman
Journal:  Biochem Biophys Res Commun       Date:  1992-02-14       Impact factor: 3.575

8.  Thrombospondin: a component of microfibrils in various tissues.

Authors:  B B Arbeille; F M Fauvel-Lafeve; M B Lemesle; D Tenza; Y J Legrand
Journal:  J Histochem Cytochem       Date:  1991-10       Impact factor: 2.479

9.  Thrombospondin levels in patients with malignancy.

Authors:  G P Tuszynski; M Smith; V L Rothman; D M Capuzzi; R R Joseph; J Katz; E C Besa; J Treat; H I Switalska
Journal:  Thromb Haemost       Date:  1992-06-01       Impact factor: 5.249

10.  Biological activities of peptides and peptide analogues derived from common sequences present in thrombospondin, properdin, and malarial proteins.

Authors:  G P Tuszynski; V L Rothman; A H Deutch; B K Hamilton; J Eyal
Journal:  J Cell Biol       Date:  1992-01       Impact factor: 10.539

View more
  15 in total

1.  Thrombospondin-1 and transforming growth factor beta-1 upregulate plasminogen activator inhibitor type 1 in pancreatic cancer.

Authors:  D Albo; D H Berger; J Vogel; G P Tuszynski
Journal:  J Gastrointest Surg       Date:  1999 Jul-Aug       Impact factor: 3.452

2.  Identification of cell adhesive active sites in the N-terminal domain of thrombospondin-1.

Authors:  P Clezardin; J Lawler; J Amiral; G Quentin; P Delmas
Journal:  Biochem J       Date:  1997-02-01       Impact factor: 3.857

Review 3.  Thrombospondins in physiology and disease: new tricks for old dogs.

Authors:  Joanne E Murphy-Ullrich; Renato V Iozzo
Journal:  Matrix Biol       Date:  2012-01-12       Impact factor: 11.583

4.  Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice.

Authors:  J Lawler; W M Miao; M Duquette; N Bouck; R T Bronson; R O Hynes
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

5.  Clinical significance of serum angiocidin levels in hepatocellular carcinoma.

Authors:  Yamini Sabherwal; Vicki L Rothman; Ronnie T P Poon; George P Tuszynski
Journal:  Cancer Lett       Date:  2006-12-22       Impact factor: 8.679

6.  Reduction of angiocidin contributes to decreased HepG2 cell proliferation.

Authors:  X G Guan; X Q Guan; K Feng; R Jian; D Tian; D Tian; H B Tong; X Sun
Journal:  Afr Health Sci       Date:  2013-09       Impact factor: 0.927

7.  The interaction of angiocidin with tissue transglutaminase.

Authors:  Darryl Z L'Heureux; Vicki L Rothman; George P Tuszynski
Journal:  Exp Mol Pathol       Date:  2009-11-18       Impact factor: 3.362

8.  Thrombospondin-1 is a transcriptional repression target of PRMT6.

Authors:  Jonathan Michaud-Levesque; Stéphane Richard
Journal:  J Biol Chem       Date:  2009-06-09       Impact factor: 5.157

9.  The novel angiogenic inhibitor, angiocidin, induces differentiation of monocytes to macrophages.

Authors:  Anita Gaurnier-Hausser; Vicki L Rothman; Svetoslav Dimitrov; George P Tuszynski
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

10.  Thrombospondin-1 (TSP-1) up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) production in human tumor cells: exploring the functional significance in tumor cell invasion.

Authors:  Anitha S John; Xioulong Hu; Vicki L Rothman; George P Tuszynski
Journal:  Exp Mol Pathol       Date:  2009-09-09       Impact factor: 3.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.